Table 4.
A comparison of percentage rates of PBMCs expressing CD69 and CD25 in subjects with psoriasis treated with biologic drugs before and during treatment (N = 28).
| PBMC Subtype | Before Treatment | During Treatment | p |
|---|---|---|---|
| Median (IQR) | Median (IQR) | ||
| CD3/CD69 | 2.86 (1.69–3.68) | 3.73 (1.61–18.83) | 0.052 |
| CD3/CD69 within CD3 | 3.74 (2.36–4.79) | 5.01 (2.16–37.84) | 0.044 |
| CD3/CD25 | 25.15 (22.99–34.79) | 29.26 (22.27–33.98) | 0.755 |
| CD3/CD25 within CD3 | 37.09 (33.28–44.26) | 41.75 (31.87–45.95) | 0.280 |
| CD4/CD69 | 1.69 (0.90–2.43) | 2.87 (1.02–11.70) | 0.019 |
| CD4/CD69 within CD4 | 3.80 (2.25–5.68) | 7.16 (2.60–42.45) | 0.005 |
| CD4/CD25 | 23.53 (18.05–32.33) | 25.11 (21.41–29.50) | 0.471 |
| CD4/CD25 within CD4 | 55.33 (49.03–66.15) | 59.65 (51.83–66.83) | 0.041 |
| CD8/CD69 | 0.21 (0.15–0.36) | 0.27 (0.11–5.72) | 0.094 |
| CD8/CD69 z CD8 | 0.94 (0.43–1.28) | 1.06 (0.34–18.06) | 0.073 |
| CD8/CD25 | 0.57 (0.42–0.97) | 0.73 (0.43–0.98) | 0.638 |
| CD8/CD25 z CD8 | 2.15 (1.35–2.76) | 2.40 (1.23–3.10) | 0.981 |
| CD19/CD69 | 0.39 (0.28–0.77) | 0.99 (0.19–4.80) | 0.004 |
| CD19/CD69 within CD19 | 6.16 (2.78–9.82) | 9.40 (2.58–45.89) | 0.006 |
| CD19/CD25 | 1.94 (1.20–2.83) | 2.34 (1.33–3.66) | 0.088 |
| CD19/CD25 within CD19 | 24.42 (16.10–30.66) | 24.46 (15.53–33.06) | 0.220 |
p for Wilcoxon rank test, IQR—interquartile range. Statistically significant correlations in bold.